Yerly Vargas-Casanova

Ms. Yerly Vargas-Casanova

Pontificia Universidad Javeriana, Bogotá, Colombia
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2023 in Frontiers in Cellular and Infection Microbiology
Verified
Journal Article
Open access
Andres Ceballos-GarzonAndres Ceballos-Garzon
Andres Ceballos-Garzon
APAna Peñuela
Ana Peñuela
SVSandra Valderrama-Beltrán
Sandra Valderrama-Beltrán
Yerly Vargas-CasanovaYerly Vargas-Casanova
Yerly Vargas-Casanova
BABEATRIZ ELENA ARIZA AYALA
BEATRIZ ELENA ARIZA AYALA
Claudia Marcela Marcela Parra-GiraldoClaudia Marcela Marcela Parra-Giraldo
Claudia Marcela Marcela Parra-Giraldo
Methods: Over a four-year period, 123 Candida bloodstream isolates were collected at a quaternary care hospital. The isolates were identified by MALDI-TOF MS and their fluconazole (FLC) susceptibility patterns were assessed according to CLSI guidelines. Subsequently, sequencing of ERG11, TAC1 or MRR1, and efflux pump activity were performed for resistant isolates.Results: Out of 123 clinical strains,C. albicans accounted for 37.4%, followed by C. tropicalis 26.8%, C. parapsilosis 19.5%, C. auris 8.1%, C. glabrata 4.1%, C. krusei 2.4% and C. lusitaniae 1.6%. Resistance to FLC reached 18%; in addition, a high proportion of isolates were cross-resistant to voriconazole. Erg11 amino acid substitutions associated with FLC-resistance (Y132F, K143R, or T220L) were found in 11/19 (58%) of FLCresistant isolates. Furthermore, novel mutations were found in all genes evaluated. Regarding efflux pumps, 8/19 (42%) of FLC-resistant Candida spp strains showed significant efflux activity. Finally, 6/19 (31%) of FLC-resistant isolates neither harbored resistance-associated mutations nor showed efflux pump activity. Among FLC-resistant species, C. auris 7/10 (70%) and C. parapsilosis 6/24 (25%) displayed the highest percentages of resistance (C. albicans 6/46, 13%).Discussion: Overall, 68% of FLC-resistant isolates exhibited a mechanism that could explain their phenotype (e.g. mutations, efflux pump activity, or both). We provide evidence that isolates from patients admitted to a Colombian hospital harbor amino acid substitutions related to resistance to one of the most commonly used molecules in the hospital setting, with Y132F being the most frequently detected.

27 July 2022 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
CCClaudia Patrícia Bravo Chaucanés
Claudia Patrícia Bravo Chaucanés
Yerly Vargas-CasanovaYerly Vargas-Casanova
Yerly Vargas-Casanova
Luis Carlos ChitivaLuis Carlos Chitiva
Luis Carlos Chitiva
Andres Ceballos-GarzonAndres Ceballos-Garzon
Andres Ceballos-Garzon
Geison CostaGeison Costa
Geison Costa
Claudia Marcela Marcela Parra-GiraldoClaudia Marcela Marcela Parra-Giraldo
Claudia Marcela Marcela Parra-Giraldo
Due to the increased incidence of fungal infections and the emergence of antifungal resistance mainly by Candida species, the need for safe and effective novel therapies is imperative. Consequently, plants and herbs are a powerful source to combat infections. Here, we evaluated the anti-Candida potential of an ethanolic extract from Piper nigrum. The phytochemical analysis of P. nigrum revealed bioactive compounds such as alkaloids, terpenoids, and tannis. Our results showed that P. nigrum extract suppressed the virulence factors of C. albicans strains, including hyphae formation in both liquid and solid media, reduced secretion of phospholipases/proteinases, and affected biofilm formation. Furthermore, the P. nigrum extract showed no hemolytic effect in vitro and exhibited reduced cytotoxicity on Vero cells and G. mellonella larvae at concentrations that inhibited hyphae and biofilm in C. albicans. Moreover, the extract demonstrated antifungal activity against C. auris strains. In conclusion, the P. nigrum extract affected the growth and morphogenesis of Candida (even in resistant strains), demonstrating that this plant has an anti-candida activity and represents a promising resource for discovering novel antifungal compounds.

30 November 2023 in Biomolecules
Verified
Journal Article
Open access
PDF file
CCClaudia Patrícia Bravo Chaucanés
Claudia Patrícia Bravo Chaucanés
Luis Carlos ChitivaLuis Carlos Chitiva
Luis Carlos Chitiva
Yerly Vargas-CasanovaYerly Vargas-Casanova
Yerly Vargas-Casanova
VSValentina Diaz Santoyo
Valentina Diaz Santoyo
AHAndrea Ximena Hernández
Andrea Ximena Hernández
Claudia Marcela Marcela Parra-GiraldoClaudia Marcela Marcela Parra-Giraldo
Claudia Marcela Marcela Parra-Giraldo
Plant-derived compounds have proven to be a source of inspiration for new drugs. In this study, piperine isolated from the fruits of Piper nigrum showed anti-Candida activity. Furthermore, the mechanisms of action of piperine and its impact on virulence factors in Candida albicans, which have not been comprehensively understood, were also assessed. Initially, piperine suppressed the hyphal transition in both liquid and solid media, hindered biofilm formation, and resulted in observable cell distortions in scanning electron microscope (SEM) samples, for both fluconazole-sensitive and fluconazole-resistant C. albicans strains. Additionally, the morphogenetic switches triggered by piperine were found to rely on the activity of mutant C. albicans strains. Secondly, piperine treatment increased cell membrane permeability and disrupted mitochondrial membrane potential, as evidenced by propidium iodine and Rhodamine 123 staining, respectively. Moreover, it induced the accumulation of intracellular reactive oxygen species in C. albicans. Synergy was obtained between the piperine and the fluconazole against the fluconazole-sensitive strain. Interestingly, there were no hemolytic effects of piperine, and it resulted in reduced cytotoxicity on fibroblast cells at low concentrations. The results suggest that piperine could have a dual mode of action inhibiting virulence factors and modulating cellular processes, leading to cell death in C. albicans.

8 April 2021 in International Journal of Peptide Research and Therapeutics
Verified
Journal Article
Closed access
PDF file
KCKaren Cárdenas-Martínez
Karen Cárdenas-Martínez
DGDerly Grueso-Mariaca
Derly Grueso-Mariaca
Yerly Vargas-CasanovaYerly Vargas-Casanova
Yerly Vargas-Casanova
LBLaura Bonilla-Velásquez
Laura Bonilla-Velásquez
SESandra Mónica Estupiñán
Sandra Mónica Estupiñán
JCJavier Garcia Castañeda
Javier Garcia Castañeda

29 June 2024 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
LSLuis Fernando Quejada Sanchez
Luis Fernando Quejada Sanchez
AHAndrea X. Hernandez
Andrea X. Hernandez
Luis Carlos ChitivaLuis Carlos Chitiva
Luis Carlos Chitiva
CCClaudia Patrícia Bravo Chaucanés
Claudia Patrícia Bravo Chaucanés
Yerly Vargas-CasanovaYerly Vargas-Casanova
Yerly Vargas-Casanova
Claudia Marcela Marcela Parra-GiraldoClaudia Marcela Marcela Parra-Giraldo
Claudia Marcela Marcela Parra-Giraldo
Invasive fungal disease causes high morbidity and mortality among immunocompromised patients. Resistance to conventional antifungal drugs and the toxicity associated with high doses highlight the need for effective antifungal therapies. In this study, the antifungal potential of the ethanolic extract of Anacardium occidentale (Cashew Leaf) leaves were evaluated against Candida albicans and C. auris. The antifungal activity was tested by the broth microdilution method and growth kinetic test. To further explore its antifungal action mode, spectrofluorophotometry, confocal microscopy and scanning and transmission electron microscopy were performed. Additionally, heterozygous knockout strains associated with resistance to oxidative stress were included in the study. We found that A. occidentale could inhibit the proliferation and growth of C. albicans at concentrations of 62.5 and 125 μg/mL. The doubling time was also drastically affected, going from 2.8 h to 22.5 h, which was also observed in C. auris. The extract induced the accumulation of intracellular reactive oxygen species (ROS), resulting in endoplasmic reticulum stress and mitochondrial dysfunction, while it did not show cytotoxicity or hemolytic activity at the concentrations evaluated. Our work preliminarily elucidated the potential mechanisms of A. occidentale against C. albicans on a cellular level, and might provide a promising option for the design of a new treatment for invasive candidiasis.

2 August 2023 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
Yerly Vargas-CasanovaYerly Vargas-Casanova
Yerly Vargas-Casanova
CCClaudia Patrícia Bravo Chaucanés
Claudia Patrícia Bravo Chaucanés
AMAndrea Ximena Hernández Martínez
Andrea Ximena Hernández Martínez
Geison CostaGeison Costa
Geison Costa
JHJORGE LUIS CONTRERAS HERRERA
JORGE LUIS CONTRERAS HERRERA
Claudia Marcela Marcela Parra-GiraldoClaudia Marcela Marcela Parra-Giraldo
Claudia Marcela Marcela Parra-Giraldo
The antifungal activity of palindromic peptide RWQWRWQWR and its derivatives was evaluated against clinical isolates of Candida albicans and C. auris. Also, Bidens pilosa ethanolic extracts of leaves and stem were evaluated. Furthermore, combinations of peptide, extract, and/or fluconazole (FLC) were evaluated. The cytotoxicity of peptides and extracts in erythrocytes and fibroblasts was determined. The original palindromic peptide, some derivative peptides, and the ethanolic extract of leaves of B. pilosa exhibited the highest activity in some of the strains evaluated. Synergy was obtained between the peptide and the FLC against C. auris 435. The combination of the extract and the original palindromic peptide against C. albicans SC5314, C. auris 435, and C. auris 537 decreased the minimal inhibitory concentrations (MICs) by a factor of between 4 and 16. These mixtures induced changes in cell morphology, such as deformations on the cell surface. The results suggest that the combination of RWQWRWQWR and B. pilosa extract is an alternative for enhancing antifungal activity and decreasing cytotoxicity and costs and should be considered to be a promising strategy for treating diseases caused by Candida spp.